Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REBECCA AREND

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1437309283
CMS profile
1303605
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$26,734.73

68 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $10,169.63 14
TESARO, Inc. $8,440.75 29
PFIZER INC. $5,245.13 3
Clovis Oncology, Inc. $2,556.30 14
Exelixis Inc. $110.06 1
AstraZeneca UK Limited $80.00 1
AstraZeneca Pharmaceuticals LP $71.07 3
Foundation Medicine, Inc. $37.31 1
Puma Biotechnology, Inc. $13.00 1
EISAI INC. $11.48 1

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REBECCA AREND

NPI 1437309283 · CMS profile ID 1303605

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437309283?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REBECCA AREND, NPI 1437309283, CMS profile ID 1303605. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437309283?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). REBECCA AREND, NPI 1437309283, CMS profile ID 1303605. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437309283?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
REBECCA AREND, NPI 1437309283, CMS profile ID 1303605, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1437309283?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

68 matching records · $26,734.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 68 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–68 of 68.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
TESARO, Inc. $91.0003/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554049 CMS
Clovis Oncology, Inc. $24.3303/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688680251 CMS
Clovis Oncology, Inc. $14.6603/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688680253 CMS
Clovis Oncology, Inc. $15.4403/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688680255 CMS
Clovis Oncology, Inc. $59.8703/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688680257 CMS
Clovis Oncology, Inc. $1,500.0003/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688680259 CMS
Clovis Oncology, Inc. $337.8703/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688680261 CMS
TESARO, Inc. $61.0302/08/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554047 CMS
TESARO, Inc. $1,100.0001/31/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554045 CMS
TESARO, Inc. $2,200.0001/26/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554029 CMS
TESARO, Inc. $462.6001/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554031 CMS
TESARO, Inc. $209.8001/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554033 CMS
TESARO, Inc. $71.9701/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554035 CMS
TESARO, Inc. $11.4001/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554037 CMS
TESARO, Inc. $40.8001/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554039 CMS
TESARO, Inc. $29.7101/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554041 CMS
TESARO, Inc. $57.2701/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675554043 CMS
PFIZER INC. $145.1301/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671924923 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,734.73 68
PY2020 $15,399.23 17
PY2021 $11,671.16 11
PY2022 $4,528.59 16
PY2023 $971.65 17
PY2024 $3,918.89 10
PY2025 $6,498.67 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,359.19 4
PY2025 Principal investigator $3,548,394.96 59
PY2024 Recipient $362.01 2
PY2024 Principal investigator $3,189,393.96 66
PY2023 Principal investigator $1,434,025.66 39
PY2022 Principal investigator $464,139.51 73
PY2021 Principal investigator $1,218,353.84 337
PY2020 Principal investigator $37,993.92 48
PY2019 Recipient $586.06 4
PY2019 Principal investigator $32,094.20 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $250,789.76 12/31/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
STUDY NAME#A Phase II Study in Newly Diagnosed Stage III,IV Epithelial Ovarian Cancer Evaluating Carbo,Taxol,Pembro in patients receiving Neoadjuvant Chemotherapy NACT followed by Olaparib,Pembro Maintenance No dispute reported 06/30/2026 1232931808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,935.88 12/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer No dispute reported 06/30/2026 1184139165
Principal investigator 1 ABBVIE INC. $406,941.00 12/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive No dispute reported 06/30/2026 1202427523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,539.95 12/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer No dispute reported 06/30/2026 1184139163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 11/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer No dispute reported 06/30/2026 1184139157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,300.00 11/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer No dispute reported 06/30/2026 1184139159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,190.00 11/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer No dispute reported 06/30/2026 1184139161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,551.60 11/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139155
Principal investigator 1 ABBVIE INC. $1,000.00 11/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer No dispute reported 06/30/2026 1202427494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 11/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139153
Principal investigator 1 ABBVIE INC. $46,540.00 11/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer No dispute reported 06/30/2026 1202427471
Principal investigator 1 GlaxoSmithKline, LLC. $59,583.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF ALABAMA AT BIRMINGHAM
A PHASE IB/II SINGLE ARM STUDY OF CABOZANTINIB PLUS DOSTARLIMAB IN WOM No dispute reported 06/30/2026 1192111627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32,640.00 11/13/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,005.42 11/13/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30,881.64 11/13/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139151
Recipient Regeneron Pharmaceuticals, Inc. $400.57 11/08/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184115177
Recipient Regeneron Pharmaceuticals, Inc. $263.67 10/18/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184115175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,885.67 10/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,011.11 10/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $63,070.00 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $277.33 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,720.00 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139137
Principal investigator 1 ABBVIE INC. $406,941.00 09/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive No dispute reported 06/30/2026 1202427423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,915.79 09/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,370.77 09/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139127
Principal investigator 1 ABBVIE INC. $310,266.00 08/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive No dispute reported 06/30/2026 1202427395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166,863.90 08/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,517.66 08/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,069.79 08/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,123.66 08/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $277.33 08/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,520.58 08/06/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,961.83 08/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139111
Recipient Regeneron Pharmaceuticals, Inc. $315.96 08/01/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184115173
Recipient Regeneron Pharmaceuticals, Inc. $378.99 07/16/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184115171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,344.79 06/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.04 06/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 06/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $715.00 06/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139109
Principal investigator 1 ABBVIE INC. $135,647.00 06/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. No dispute reported 06/30/2026 1202427337
Principal investigator 1 ABBVIE INC. $271,294.00 06/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. No dispute reported 06/30/2026 1202427325
Principal investigator 1 ABBVIE INC. $67,823.50 05/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. No dispute reported 06/30/2026 1202427289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $170.00 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139097
Principal investigator 1 ABBVIE INC. $203,470.50 05/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. No dispute reported 06/30/2026 1202427282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,487.79 05/08/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36,041.07 05/08/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 04/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $277.33 04/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28,092.29 04/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139087
Principal investigator 1 GlaxoSmithKline, LLC. $59,583.68 04/15/2025 Non-covered Recipient Entity
UNIVERSITY OF ALABAMA AT BIRMINGHAM
A PHASE IB/II SINGLE ARM STUDY OF CABOZANTINIB PLUS DOSTARLIMAB IN WOM No dispute reported 06/30/2026 1192171884
Principal investigator 1 ABBVIE INC. $67,823.50 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. No dispute reported 06/30/2026 1202427264
Principal investigator 1 ABBVIE INC. $67,823.50 04/08/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. No dispute reported 06/30/2026 1202427257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44,546.58 03/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,450.68 03/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139081
Principal investigator 1 ABBVIE INC. $310,266.00 03/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A25-401 - Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive No dispute reported 06/30/2026 1202427227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,831.63 02/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139077
Principal investigator 1 ABBVIE INC. $67,823.50 02/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. No dispute reported 06/30/2026 1202427207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,277.86 02/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.04 02/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $277.33 02/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.89 02/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65,687.79 02/06/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184139067